PR84139

SEOUL, South Korea, May 26, 2020 /PRNewswire=KYODO JBN/ --

Veeva Vault QualityDocs gives IVI better control and real time visibility into

documents and processes for audits

Veeva Systems (NYSE: VEEV) today announced that the International Vaccine

Institute (IVI), a not-for-profit International Organization established in

1997 as an initiative by the United Nations Development Programme (UNDP), has

implemented Veeva Vault QualityDocs to improve control and real time visibility

of standard operating procedures (SOPs) for audits and inspections. The move

from paper-based processes to Vault QualityDocs will better enable IVI to meet

compliance and GxP requirements of major drug administrations.

Vault QualityDocs, a modern, cloud application for GxP document control and

management, will enable IVI to deliver greater compliance, improved quality,

and reduced operational overhead. IVI can accelerate the review and approval

workflows of SOPs and easily share GxP documents among employees and partners.

Vault QualityDocs is part of Veeva Vault Quality Suite which unifies quality

processes, document control, and training, to drive global operational

innovation.

"Veeva allows our organisation to improve compliance and ensure all SOP and

company documents are stored in one validated system that is compliant with the

FDA's 21 CFR part 11 regulation," said Tobin Guarnacci, head of quality

management GxP at IVI. "We now have a single source of truth that helps us and

our partners be audit-ready."

"Veeva will enable IVI to increase operational efficiencies and improve quality

processes with an easy to use and manage cloud solution," said Chris Shim, Vice

President, Vault R&D APAC & China. "We are honoured to partner with them and

help achieve their mission to develop safe, effective, and affordable vaccines

for global public health."

Learn more about how Veeva Vault QualityDocs is helping life sciences

organisations provide superior ease-of-use and seamless collaboration at

veeva.com/qualitydocs.

About the International Vaccine Institute

The International Vaccine Institute (IVI) is a nonprofit inter-governmental

organization established in 1997 as an initiative of the United Nations

Development Programme (UNDP). Headquartered in Seoul, South Korea, IVI was the

first international organization hosted by Korea. IVI has 35 signatory

countries and the World Health Organization (WHO) on its treaty, including

Korea, Sweden and India as state funders.

Our mandate is to make vaccines available and accessible for the world's most

vulnerable people, focusing on infectious diseases of global health importance

such as cholera, typhoid, shigella, salmonella, schistosomiasis, Group A Strep,

Hepatitis A, HPV, TB, HIV, MERS-CoV, as well as antimicrobial resistance.

Website: https://www.ivi.int

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life

sciences industry. Committed to innovation, product excellence, and customer

success, Veeva serves more than 850 customers, ranging from the world's largest

pharmaceutical companies to emerging biotechs. Veeva is headquartered in the

San Francisco Bay Area, with offices throughout North America, Europe, Asia,

and Latin America. Please visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market demand

for and acceptance of Veeva's products and services, the results from use of

Veeva's products and services, and general business conditions, particularly in

the life sciences industry. Any forward-looking statements contained in this

press release are based upon Veeva's historical performance and its current

plans, estimates, and expectations, and are not a representation that such

plans, estimates, or expectations will be achieved. These forward-looking

statements represent Veeva's expectations as of the date of this press

announcement. Subsequent events may cause these expectations to change, and

Veeva disclaims any obligation to update the forward-looking statements in the

future. These forward-looking statements are subject to known and unknown risks

and uncertainties that may cause actual results to differ materially.

Additional risks and uncertainties that could affect Veeva's financial results

are included under the captions, "Risk Factors" and "Management's Discussion

and Analysis of Financial Condition and Results of Operations," in the

company's filing on Form 10-K for the period ended January 31, 2020. This is

available on the company's website at veeva.com under the Investors section and

on the SEC's website at sec.gov. Further information on potential risks that

could affect actual results will be included in other filings Veeva makes with

the SEC from time to time.

Contact:

Jacqueline Davis

Veeva Systems

+61-411284900

jacqueline.davis@veeva.com

SOURCE  Veeva Systems

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=364121

   Caption: Veeva Logo